Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia.

Journal

Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895

Informations de publication

Date de publication:
Sep 2020
Historique:
pubmed: 8 3 2020
medline: 8 3 2020
entrez: 8 3 2020
Statut: ppublish

Résumé

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Identifiants

DOI: 10.1038/s41375-020-0782-4 PMID: 32144400
pubmed: 32144400
doi: 10.1038/s41375-020-0782-4
pii: 10.1038/s41375-020-0782-4
doi:

Types de publication

Published Erratum

Langues

eng

Sous-ensembles de citation

IM

Pagination

2543

Commentaires et corrections

Type : ErratumFor

Auteurs

Ellen Weisberg (E)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. ellen_weisberg@dfci.harvard.edu.
Department of Medicine, Harvard Medical School, Boston, MA, USA. ellen_weisberg@dfci.harvard.edu.
ORCID: 0000-0002-5679-9531

Chengcheng Meng (C)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Abigail Case (A)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Martin Sattler (M)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medicine, Harvard Medical School, Boston, MA, USA.

Hong L Tiv (HL)

Experimental Therapeutic Core, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA, 02215.

Prafulla C Gokhale (PC)

Experimental Therapeutic Core, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA, 02215.

Sara Buhrlage (S)

Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA, 02215.

Jinhua Wang (J)

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.

Nathanael Gray (N)

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
ORCID: 0000-0001-5354-7403

Richard Stone (R)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medicine, Harvard Medical School, Boston, MA, USA.

Suiyang Liu (S)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Shripad V Bhagwat (SV)

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA.

Ramon V Tiu (RV)

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA.

Sophia Adamia (S)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medicine, Harvard Medical School, Boston, MA, USA.

James D Griffin (JD)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. james_griffin@dfci.harvard.edu.
Department of Medicine, Harvard Medical School, Boston, MA, USA. james_griffin@dfci.harvard.edu.

Classifications MeSH